{
  "doc_id": "9_electrolytedisorders__9bbd67",
  "original_filename": "9_ElectrolyteDisorders.pdf",
  "md_path": "data/parsed/9_ElectrolyteDisorders/9_ElectrolyteDisorders.md",
  "rmd_path": "data/parsed/9_ElectrolyteDisorders/9_ElectrolyteDisorders.rmd",
  "blocks": [
    {
      "type": "heading",
      "level": 1,
      "section": "NUTRITION SUPPORT CERTIFICATE",
      "line": 0
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Electrolyte Disorders",
      "line": 2
    },
    {
      "type": "image",
      "section": "Electrolyte Disorders",
      "line": 4,
      "content": "![img-0.jpeg](images/dc1fa49c6d641dce.png)"
    },
    {
      "type": "text",
      "section": "Electrolyte Disorders",
      "line": 6,
      "preview": "Planned by the American Society of Health-System Pharmacists (ASHP) in collaboration with the Americ"
    },
    {
      "type": "text",
      "section": "Electrolyte Disorders",
      "line": 7,
      "preview": "(c)2022 American Society of Health-System Pharmacists, Inc. All rights reserved."
    },
    {
      "type": "text",
      "section": "Electrolyte Disorders",
      "line": 9,
      "preview": "No part of this publication may be reproduced or transmitted in any form or by any means, electronic"
    },
    {
      "type": "text",
      "section": "Electrolyte Disorders",
      "line": 11,
      "preview": "--- page 1 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "NUTRITION SUPPORT COMPLICATIONS: ELECTROLYTE DISORDERS",
      "line": 13
    },
    {
      "type": "text",
      "section": "NUTRITION SUPPORT COMPLICATIONS: ELECTROLYTE DISORDERS",
      "line": 15,
      "preview": "Anne M. Tucker, Pharm.D., BCNSP"
    },
    {
      "type": "text",
      "section": "NUTRITION SUPPORT COMPLICATIONS: ELECTROLYTE DISORDERS",
      "line": 16,
      "preview": "University of Texas MD Anderson Cancer Center"
    },
    {
      "type": "text",
      "section": "NUTRITION SUPPORT COMPLICATIONS: ELECTROLYTE DISORDERS",
      "line": 18,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 20
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 22,
      "preview": "The following persons in control of this activity's content have relevant financial relationships:"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 24,
      "preview": "- Jay Mirtallo: Fresenius Kabi, consultant"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 26,
      "preview": "All other persons in control of content do not have any relevant financial relationships with an ine"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 28,
      "preview": "As defined by the Standards of Integrity and Independence definition of ineligible company. All rele"
    },
    {
      "type": "text",
      "section": "RELEVANT FINANCIAL RELATIONSHIP DISCLOSURE",
      "line": 30,
      "preview": "--- page 2 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "LEARNING OBJECTIVES",
      "line": 32
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 34,
      "preview": "- Analyze patient information to determine the type of electrolyte disorder."
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 35,
      "preview": "- Describe common etiologies of electrolyte disorders and their impact on the nutrition prescription"
    },
    {
      "type": "text",
      "section": "LEARNING OBJECTIVES",
      "line": 36,
      "preview": "- Design recommendations for the prevention and management of electrolyte disorders."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "KEY ABBREVIATIONS",
      "line": 39
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 41,
      "preview": "- ACEI:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 42,
      "preview": "- AdjBW:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 43,
      "preview": "- AKI:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 44,
      "preview": "- ARB:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 45,
      "preview": "- ATPase:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 46,
      "preview": "- CKD:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 47,
      "preview": "- $\\mathrm{CO}_{2}$ :"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 48,
      "preview": "- ECF:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 49,
      "preview": "- ECG: angiotensin converting enzyme inhibitor"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 50,
      "preview": "adjusted body weight"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 51,
      "preview": "acute kidney injury"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 52,
      "preview": "angiotensin receptor blocker"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 53,
      "preview": "adenosine triphosphatase"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 54,
      "preview": "chronic kidney disease"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 55,
      "preview": "carbon dioxide"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 56,
      "preview": "extracellular fluid"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 57,
      "preview": "electrocardiogram"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 59,
      "preview": "--- page 3 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "KEY ABBREVIATIONS",
      "line": 61
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 63,
      "preview": "- IBW:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 64,
      "preview": "- ICF:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 65,
      "preview": "- NSAID:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 66,
      "preview": "- PN:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 67,
      "preview": "- RRT:"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 68,
      "preview": "ideal body weight"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 69,
      "preview": "intracellular fluid"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 70,
      "preview": "non-steroidal anti-inflammatory drug"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 71,
      "preview": "parenteral nutrition"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 72,
      "preview": "renal replacement therapy"
    },
    {
      "type": "text",
      "section": "KEY ABBREVIATIONS",
      "line": 74,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 76
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 78,
      "preview": "| Electrolyte | Adult |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 79,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 80,
      "preview": "| Sodium | $135-145 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 81,
      "preview": "| Potassium | $3.5-5 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 82,
      "preview": "| Chloride | $98-108 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 83,
      "preview": "| $\\mathrm{CO}_{2}$ | $23-30 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 84,
      "preview": "| Calcium | $9-10.5 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 85,
      "preview": "| Phosphorus | $2.5-4.5 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 86,
      "preview": "| Magnesium | $1.7-2.4 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 87,
      "preview": "| *Variations in lab values exist between institutions |  |"
    },
    {
      "type": "text",
      "section": "NORMAL ELECTROLYTE CONCENTRATIONS",
      "line": 89,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 91
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 93,
      "preview": "| Electrolyte | Requirements |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 94,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 95,
      "preview": "| Sodium | $60-100 \\mathrm{mEq} /$ day or $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 96,
      "preview": "| Potassium | $60-100 \\mathrm{mEq} /$ day or $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 97,
      "preview": "| Chloride | As needed to maintain acid-base balance |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 98,
      "preview": "| Acetate | As needed to maintain acid-base balance |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 99,
      "preview": "| Calcium | $10-15 \\mathrm{mEq} /$ day |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 100,
      "preview": "| Phosphorus | $20-40 \\mathrm{mmol} /$ dayor $0.25-0.5 \\mathrm{mmol} / \\mathrm{kg} /$ day |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 101,
      "preview": "| Magnesium | $8-20 \\mathrm{mEq} /$ day or $0.25-0.5 \\mathrm{mEq} / \\mathrm{kg} /$ day |"
    },
    {
      "type": "table",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 102,
      "preview": "| *Consider lower doses for those with renal insufficiency |  |"
    },
    {
      "type": "text",
      "section": "ADULT ELECTROLYTE REQUIREMENTS",
      "line": 104,
      "preview": "Mirtallo J et al.JPEN J ParentEnteral Nutr. 2004; 28:S39-S70."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 106
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 108,
      "preview": "- Renal dysfunction"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 109,
      "preview": "- Empiric dose - 50\\% recommended dose"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 110,
      "preview": "- Obesity"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 111,
      "preview": "- Adjusted body weight (AdjBW) for weight-based electrolyte dosing"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 112,
      "preview": "- AdjBW $=[($ weight in $\\mathrm{kg}-\\mathrm{IBW}) \\times 0.25]+\\mathrm{IBW}$"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 113,
      "preview": "- Electrolyte disorders"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 114,
      "preview": "- Acute (< 48 hours) vs. chronic (> 48 hours)"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 115,
      "preview": "- Rate of development, degree of abnormality and/or symptoms"
    },
    {
      "type": "text",
      "section": "ELECTROLYTE DOSING CONSIDERATIONS",
      "line": 117,
      "preview": "--- page 5 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "POTASSIUM",
      "line": 119
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 121,
      "preview": "- Most abundant intracellular cation"
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 122,
      "preview": "- Normal serum potassium $3.5-5 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 123,
      "preview": "- Normal intracellular concentration $150 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 124,
      "preview": "- Functions in maintaining resting membrane potential, metabolism, protein and glycogen synthesis"
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 125,
      "preview": "- Na-K-ATPase pump regulates entry of K into the cell"
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 126,
      "preview": "- Intracellular shift: insulin, beta 2 agonists, alkalosis"
    },
    {
      "type": "text",
      "section": "POTASSIUM",
      "line": 127,
      "preview": "- Extracellular shift: glucagon, acidosis, aldosterone (allows renal elimination)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 130
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 132,
      "preview": "- Common electrolyte disorder"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 133,
      "preview": "- Symptoms - cardiovascular and neuromuscular in nature"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 134,
      "preview": "- ECG changes: prolonged QRS, ST-segment \\& T-wave depression, U waves"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 135,
      "preview": "- Arrhythmias: atrial fibrillation, ventricular tachycardia/fibrillation"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 136,
      "preview": "- Muscle weakness, cramps, paralysis"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 137,
      "preview": "- Rhabdomyolysis"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 138,
      "preview": "- Intestinal ileus"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA (K < 3.5 MEQ/L)",
      "line": 140,
      "preview": "--- page 6 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 142
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 144,
      "preview": "- Less common than hypokalemia"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 145,
      "preview": "- Symptoms - cardiovascular and neuromuscular in nature"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 146,
      "preview": "- ECG changes: peaked T waves, QRS widening, loss of P wave"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 147,
      "preview": "- Arrhythmias: ventricular fibrillation, asystole"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 148,
      "preview": "- Muscle weakness, paralysis"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA (K > 5 MEQ/L)",
      "line": 150,
      "preview": "Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum 3rd ed. 2017:113-37."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 152
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 154,
      "preview": "Hypokalemia ( $\\mathrm{K}<3.5 \\mathrm{mEq} / \\mathrm{L}$ )"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 156,
      "preview": "- Poor intake"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 157,
      "preview": "- Increased renal excretion"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 158,
      "preview": "- K-wasting diuretics, aldosterone, amphotericin B, aminoglycosides"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 159,
      "preview": "- Renal replacement therapy (RRT)"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 160,
      "preview": "- Gl losses"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 161,
      "preview": "- Diarrhea (stool 10 mEq K/L)"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 162,
      "preview": "- Emesis/NG (up to $50 \\mathrm{mEq} \\mathrm{K/L}$ )"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 163,
      "preview": "- Intracellular shift"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 164,
      "preview": "- Alkalosis, insulin, beta agonists"
    },
    {
      "type": "text",
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 166,
      "preview": "--- page 7 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "POTASSIUM DISORDERS ETIOLOGY",
      "line": 168
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 170
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 172,
      "preview": "- Excessive intake"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 173,
      "preview": "- Decreased renal excretion"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 174,
      "preview": "- AKI, Stage 4/5 CKD"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 175,
      "preview": "- ACEI, ARBs, aldosterone antagonists, renin inhibitors, NSAIDs"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 176,
      "preview": "- K-sparing diuretics, trimethoprim, tacrolimus"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 177,
      "preview": "- Extracellular shift"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 178,
      "preview": "- Beta blockers, succinylcholine"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 179,
      "preview": "- Cellular disruption"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 180,
      "preview": "- Acidosis"
    },
    {
      "type": "text",
      "section": "Hyperkalemia ( $\\mathrm{K}>5 \\mathrm{mEq} / \\mathrm{L}$ )",
      "line": 182,
      "preview": "Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 184
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 186,
      "preview": "- Dietary modification, salt substitutes"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 187,
      "preview": "- Check for hypomagnesemia and replace first as indicated"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 188,
      "preview": "- Oral potassium therapy"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 189,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 190,
      "preview": "- Gastrointestinal adverse effect - large doses should be divided"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 191,
      "preview": "- Parenteral potassium therapy"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 192,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 193,
      "preview": "- Adverse effects - phlebitis, hyperkalemia, arrhythmias"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 194,
      "preview": "- Potassium-sparing diuretics"
    },
    {
      "type": "text",
      "section": "HYPOKALEMIA MANAGEMENT",
      "line": 196,
      "preview": "--- page 8 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PARENTERAL POTASSIUM",
      "line": 198
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 200,
      "preview": "- Empiric potassium dose in PN: 1-2 mEq/kg/day"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 201,
      "preview": "- Decrease dose by 50\\% in renal impairment"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 202,
      "preview": "- 10 mEq of K intravenously increases serum K by $\\sim 0.1 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 203,
      "preview": "- Assumes normal renal and gastrointestinal function"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 204,
      "preview": "- Dilution"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 205,
      "preview": "- Sodium chloride-containing solutions"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 206,
      "preview": "- Peripheral IV infusion: dilute $10 \\mathrm{mEq} \\mathrm{K} / 100 \\mathrm{~mL}$ maximum"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 207,
      "preview": "- Central IV infusion: can give more concentrated; check institutional policy"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 208,
      "preview": "- Infusion rates"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 209,
      "preview": "- $\\leq 10 \\mathrm{mEq} / \\mathrm{hr}$ : no cardiac monitoring / peripheral IV access"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 210,
      "preview": "- $>10 \\mathrm{mEq} / \\mathrm{hr}$ : cardiac monitoring / central IV access"
    },
    {
      "type": "text",
      "section": "PARENTERAL POTASSIUM",
      "line": 212,
      "preview": "Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 214
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 216,
      "preview": "- Dietary modifications"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 217,
      "preview": "- Identify and eliminate cause"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 218,
      "preview": "- Medication therapy directed at hyperkalemia management"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 219,
      "preview": "- Cardiac stabilization (does not reduce serum potassium levels)"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 220,
      "preview": "- ECF to ICF shift"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 221,
      "preview": "- Potassium elimination"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 223,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 225
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 227,
      "preview": "| Agent | Dose / Route | Onset / Duration |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 228,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 229,
      "preview": "| Myocardial stabilization | 1-2 grams IV | $1-2 \\mathrm{~min} / 10-30 \\mathrm{~min}$ |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 230,
      "preview": "| Calcium gluconate | 10 units IV <br> 25 gram IV |  |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 231,
      "preview": "| Cellular incorporation (ECF to ICF shift) | 15-45 min / 2-6 hours |  |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 232,
      "preview": "| Regular insulin $\\pm$ <br> Dextrose 50\\% | $50-100 \\mathrm{mEq} \\mathrm{IV}$ | $30 \\mathrm{~min} /"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 233,
      "preview": "| Sodium bicarbonate | $10-20 \\mathrm{mg}$ nebulized | $30 \\mathrm{~min} / 1-2$ hours |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 234,
      "preview": "| Albuterol |  |  |"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 236,
      "preview": "HYPERKALEMIA MANAGEMENT"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 238,
      "preview": "| Agent | Dose / Route | Onset / Duration |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 239,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 240,
      "preview": "| Increase potassium elimination | $20-40 \\mathrm{mg} \\mathrm{IV}$ |  |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 241,
      "preview": "| Furosemide | $5-15 \\mathrm{~min} / 4-6$ hours |  |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 242,
      "preview": "| Sodium polystyrene sulfonate | $15-60$ grams PO or PR | $60 \\mathrm{~min} / 4-6$ hours |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 243,
      "preview": "| Patiromer (not for acute use) | 8.4 grams PO daily | 7 hours / 24 hours |"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 244,
      "preview": "| Sodium zirconium cyclosilicate (not for <br> acute use) | 10 grams PO 3 times daily <br> x 48 hour"
    },
    {
      "type": "table",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 245,
      "preview": "| Hemodialysis | 2-4 hours | Immediate / Variable |"
    },
    {
      "type": "text",
      "section": "HYPERKALEMIA MANAGEMENT",
      "line": 247,
      "preview": "--- page 10 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 249
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 251,
      "preview": "A patient presents with serum potassium of $6 \\mathrm{mEq} / \\mathrm{L}$ and peaked T-waves on ECG. "
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 252,
      "preview": "A. Insulin"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 253,
      "preview": "B. Sodium bicarbonate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 254,
      "preview": "C. Calcium gluconate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 255,
      "preview": "D. Sodium polystyrene sulfate"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "MAGNESIUM",
      "line": 257
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 259,
      "preview": "- Intracellular cation"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 260,
      "preview": "- Normal serum magnesium 1.7-2.4 mg/dL"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 261,
      "preview": "- Absorbed in the jejunum"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 262,
      "preview": "- Regulated by the kidney"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 263,
      "preview": "- Important as enzyme cofactor, nature's calcium blocker, neuromuscular transmission and cardiovascu"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 264,
      "preview": "- Maintaining high-normal range serum $\\mathrm{Mg} \\sim 2.7 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 265,
      "preview": "- Reduces ventricular ectopy"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 266,
      "preview": "- Improves $\\mathrm{K}^{+}$retention"
    },
    {
      "type": "text",
      "section": "MAGNESIUM",
      "line": 268,
      "preview": "--- page 11 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 270
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 272,
      "preview": "- Common electrolyte disorder"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 273,
      "preview": "- Up to 65\\% ICU patients experience hypomagnesemia"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 274,
      "preview": "- Symptoms - cardiovascular and neuromuscular in nature"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 275,
      "preview": "- Refractory hypokalemia and hypocalcemia"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 276,
      "preview": "- Hyperreflexia, muscle weakness, cramps"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 277,
      "preview": "- Tetany, seizures, coma"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 278,
      "preview": "- ECG changes: increased PR and QRS, prolonged QT interval, U waves"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA (MG < 1.7 MG/DL)",
      "line": 279,
      "preview": "- Arrhythmias, atrial fibrillation, ventricular fibrillation, Torsade de pointes"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 282
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 284,
      "preview": "- Symptomatic cases are rare"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 285,
      "preview": "- Symptoms - related to loss of muscle tone"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 286,
      "preview": "- Not typically observed until serum $\\mathrm{Mg}>4-5 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 287,
      "preview": "- Hypotension"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 288,
      "preview": "- Hyporeflexia, muscle weakness, paralysis"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 289,
      "preview": "- Somnolence, coma"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA (MG > 2.4 MG/DL)",
      "line": 291,
      "preview": "--- page 12 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 293
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 295,
      "preview": "Hypomagnesemia ( $\\mathrm{Mg}<1.7 \\mathrm{mg} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 297,
      "preview": "- Poor intake"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 298,
      "preview": "- Malabsorption or gastrointestinal loss"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 299,
      "preview": "- Small bowel diseases, gastric bypass, alcoholism, laxatives, diarrhea"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 300,
      "preview": "- Renal replacement therapy (RRT)"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 301,
      "preview": "- Increased renal excretion"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 302,
      "preview": "- Renal tubular disorders"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 303,
      "preview": "- Amphotericin B, aminoglycosides, cyclosporine, cisplatin, diuretics, foscarnet"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 304,
      "preview": "- Intracellular shift (insulin)"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY",
      "line": 306,
      "preview": "Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum 3rd ed. 2017:113-37."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 308
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 310,
      "preview": "Hypermagnesemia ( $\\mathrm{Mg}>2.4 \\mathrm{mg} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 312,
      "preview": "- Excessive intake"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 313,
      "preview": "- Decreased renal excretion"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 314,
      "preview": "- AKI, Stage 4/5 CKD, end stage renal disease (ESRD)"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 315,
      "preview": "- Tumor lysis syndrome"
    },
    {
      "type": "text",
      "section": "MAGNESIUM DISORDERS ETIOLOGY, CONT.",
      "line": 317,
      "preview": "--- page 13 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 319
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 321,
      "preview": "- Dietary modification"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 322,
      "preview": "- Oral magnesium therapy"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 323,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 324,
      "preview": "- Magnesium oxide and magnesium hydroxide"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 325,
      "preview": "- Adverse effect - abdominal cramping, diarrhea"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 326,
      "preview": "- May be difficult to replace magnesium deficits orally if large doses for multiple days are require"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 327,
      "preview": "- Parenteral magnesium therapy"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 328,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOMAGNESEMIA MANAGEMENT",
      "line": 329,
      "preview": "- Adverse effects - phlebitis, injection site pain"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "PARENTERAL MAGNESIUM",
      "line": 332
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 334,
      "preview": "- Decrease dose by $50 \\%$ in renal impairment"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 335,
      "preview": "- Empiric magnesium dose in PN: 0.25-0.5 mEq/kg/day"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 336,
      "preview": "- 8 mEq of Mg intravenously increases serum Mg by $\\sim 0.1 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 337,
      "preview": "- Assumes normal renal and gastrointestinal function"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 338,
      "preview": "- Dosing"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 339,
      "preview": "- Serum Mg 1-1.5 mg/dL: 8-32 mEq, up to $1 \\mathrm{mEq} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 340,
      "preview": "- Serum Mg < $1 \\mathrm{mg} / \\mathrm{dL}$ : 32-64 mEq, up to $1.5 \\mathrm{mEq} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 341,
      "preview": "- Infusion rates"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 342,
      "preview": "- $\\leq 8 \\mathrm{mEq}$ Mg per hour"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 343,
      "preview": "- Prevents renal wasting and infusion reactions"
    },
    {
      "type": "text",
      "section": "PARENTERAL MAGNESIUM",
      "line": 345,
      "preview": "--- page 14 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 347
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 349,
      "preview": "- Limit magnesium intake"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 350,
      "preview": "- Increase magnesium elimination"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 351,
      "preview": "- Volume expansion"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 352,
      "preview": "- Loop diuretics"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 353,
      "preview": "- RRT"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 354,
      "preview": "- Direct magnesium antagonist"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 355,
      "preview": "- Calcium chloride, calcium gluconate"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 356,
      "preview": "- Supportive care measures"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 357,
      "preview": "- Vasopressor therapy"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 358,
      "preview": "- Mechanical ventilation"
    },
    {
      "type": "text",
      "section": "HYPERMAGNESEMIA TREATMENT",
      "line": 360,
      "preview": "Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 362
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 364,
      "preview": "Upon morning review of a parenteral nutrition patient, it is noted that the serum magnesium is $1.5 "
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 365,
      "preview": "A. No dose is indicated"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 366,
      "preview": "B. 16 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 367,
      "preview": "C. 32 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 368,
      "preview": "D. 48 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 370,
      "preview": "--- page 15 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PHOSPHORUS",
      "line": 372
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 374,
      "preview": "- Intracellular anion"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 375,
      "preview": "- Normal serum phosphorus $2.5-4.5 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 376,
      "preview": "- Essential part of phospholipid membranes, metabolism, ATP production, 2,3diphosphoglycerate regula"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 377,
      "preview": "- Hormonal regulation"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 378,
      "preview": "- Vitamin D"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 379,
      "preview": "- Parathyroid hormone"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS",
      "line": 380,
      "preview": "- Calcitonin"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 383
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 385,
      "preview": "- 30-100\\% nutrition support patients experience hypophophatemia"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 386,
      "preview": "- Symptoms - cardiovascular and neuromuscular in nature"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 387,
      "preview": "- Paresthesia, muscle weakness"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 388,
      "preview": "- Cardiomyopathy"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 389,
      "preview": "- Red blood cell breakdown"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 390,
      "preview": "- Acute respiratory failure"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 391,
      "preview": "- Rhabdomyolysis"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 392,
      "preview": "- Seizures, coma"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA (P < 2.5 MG/DL)",
      "line": 394,
      "preview": "--- page 16 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 396
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 398,
      "preview": "- Symptomatic cases are rare"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 399,
      "preview": "- Symptoms"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 400,
      "preview": "- Soft tissue calcifications"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 401,
      "preview": "- Nephrolithiasis"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 402,
      "preview": "- Obstructive uropathy"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA (P > 4.5 MG/DL)",
      "line": 403,
      "preview": "- Hypocalcemia (tetany)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 406
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 408,
      "preview": "Hypophosphatemia ( $\\mathrm{P}<2.5 \\mathrm{mg} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 410,
      "preview": "- Poor intake"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 411,
      "preview": "- Poor absorption"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 412,
      "preview": "- Phosphate binders, vitamin D deficiency, laxatives, diarrhea"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 413,
      "preview": "- Increased renal excretion"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 414,
      "preview": "- Hyperparathyroidism, burns"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 415,
      "preview": "- Diuretics, corticosteroids, foscarnet"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 416,
      "preview": "- RRT"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 417,
      "preview": "- Intracellular shift"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 418,
      "preview": "- Insulin, calcitonin"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY",
      "line": 420,
      "preview": "--- page 17 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 422
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 424,
      "preview": "Hyperphosphatemia ( $\\mathbf{P > 4 . 5 ~ m g} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 426,
      "preview": "- Excessive intake"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 427,
      "preview": "- Excessive vitamin D intake"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 428,
      "preview": "- Decreased renal excretion"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 429,
      "preview": "- AKI, Stage 4/5 CKD, end stage renal disease (ESRD)"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 430,
      "preview": "- Tumor lysis syndrome"
    },
    {
      "type": "text",
      "section": "PHOSPHORUS DISORDERS ETIOLOGY, CONT.",
      "line": 432,
      "preview": "Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum 3rd ed. 2017:113-37."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 434
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 436,
      "preview": "- Oral phosphate therapy"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 437,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 438,
      "preview": "- Neutraphos, KPhos neutral, sodium phosphate liquid"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 439,
      "preview": "- Adverse effect - abdominal cramping, osmotic diarrhea"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 440,
      "preview": "- Parenteral phosphate therapy"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 441,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOPHOSPHATEMIA MANAGEMENT",
      "line": 443,
      "preview": "--- page 18 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PARENTERAL PHOSPHATE",
      "line": 445
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 447,
      "preview": "- Decrease dose by $50 \\%$ in renal impairment"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 448,
      "preview": "- Empiric phosphate dose in PN: 0.25-0.5 mmol/kg/day"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 449,
      "preview": "- Check Na and K to determine appropriate phosphate salt"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 450,
      "preview": "- $1 \\mathrm{mmol} \\mathrm{K}_{3} \\mathrm{PO}_{4}=1.5 \\mathrm{mEq} \\mathrm{K}$"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 451,
      "preview": "- $1 \\mathrm{mmol} \\mathrm{NaPO}_{4}=1.33 \\mathrm{mEq} \\mathrm{Na}$"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 452,
      "preview": "- Phosphorus replacement dosing"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 453,
      "preview": "- Serum P 2.3-2.7 mg/dL: 0.08-0.16 mmol/kg"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 454,
      "preview": "- Serum P 1.5-2.2 mg/dL: 0.16-0.32 mmol/kg"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 455,
      "preview": "- Serum P 2.3-2.7 mg/dL: 0.32-0.64 mmol/kg"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 456,
      "preview": "- Infusion rate $\\leq 7$ mmol phosphate per hour"
    },
    {
      "type": "text",
      "section": "PARENTERAL PHOSPHATE",
      "line": 458,
      "preview": "Clark CL, et al. Crit Care Med 1995;23:1504-10."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 460
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 462,
      "preview": "- Limit phosphorus intake"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 463,
      "preview": "- Phosphorus binders"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 464,
      "preview": "- Symptomatic hypocalcemia (tetany)"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 465,
      "preview": "- Calcium chloride, calcium gluconate"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 466,
      "preview": "- Renal replacement therapy"
    },
    {
      "type": "text",
      "section": "HYPERPHOSPHATEMIA TREATMENT",
      "line": 468,
      "preview": "--- page 19 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#3",
      "line": 470
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 472,
      "preview": "Assuming normal renal function, how much will 30 mmol of potassium phosphate increase the serum pota"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 473,
      "preview": "A. $0.15 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 474,
      "preview": "B. $0.3 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 475,
      "preview": "C. $0.45 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 476,
      "preview": "D. $0.6 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "CALCIUM",
      "line": 478
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 480,
      "preview": "- Intracellular cation"
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 481,
      "preview": "- Normal serum calcium 9-10.5 mg/dL"
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 482,
      "preview": "- Normal serum ionized serum calcium"
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 483,
      "preview": "- $4.4-5.4 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 484,
      "preview": "- 1.1-1.35 mmol/L"
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 485,
      "preview": "- Essential for bone mineralization and growth, coagulation, platelet adhesion, propagation of neuro"
    },
    {
      "type": "text",
      "section": "CALCIUM",
      "line": 487,
      "preview": "--- page 20 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "CALCIUM, CONT.",
      "line": 489
    },
    {
      "type": "text",
      "section": "CALCIUM, CONT.",
      "line": 491,
      "preview": "- Regulation"
    },
    {
      "type": "text",
      "section": "CALCIUM, CONT.",
      "line": 492,
      "preview": "- Vitamin D"
    },
    {
      "type": "text",
      "section": "CALCIUM, CONT.",
      "line": 493,
      "preview": "- Parathyroid hormone"
    },
    {
      "type": "text",
      "section": "CALCIUM, CONT.",
      "line": 494,
      "preview": "- Calcitonin"
    },
    {
      "type": "text",
      "section": "CALCIUM, CONT.",
      "line": 495,
      "preview": "- Phosphorus"
    },
    {
      "type": "text",
      "section": "CALCIUM, CONT.",
      "line": 496,
      "preview": "- pH (affects albumin binding)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 499
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 501,
      "preview": "- Common in critically ill"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 502,
      "preview": "- Albumin-corrected $\\mathrm{Ca}^{2+}$ equation (not reliable in critically ill)"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 503,
      "preview": "- Corrected $\\mathrm{Ca}^{2+}=0.8$ (4 - measured albumin) + measured $\\mathrm{Ca}^{2+}$"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 504,
      "preview": "- Symptoms - cardiovascular and neuromuscular in nature"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 505,
      "preview": "- Paresthesia (oral), tetany, muscle cramps"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 506,
      "preview": "- Cardiovascular"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 507,
      "preview": "- Depression, anxiety, memory loss, confusion"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 508,
      "preview": "- Skin, hair, and nail changes"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA (CA < 9 MG/DL)",
      "line": 510,
      "preview": "--- page 21 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 512
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 514,
      "preview": "- Poor intake"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 515,
      "preview": "- Hypoparathyroidism"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 516,
      "preview": "- Decreased bone resorption"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 517,
      "preview": "- Bisphosphonates, calcitonin"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 518,
      "preview": "- Vitamin D deficiency"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 519,
      "preview": "- Poor intake of vitamin D"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 520,
      "preview": "- Reduced sunlight exposure"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 521,
      "preview": "- CKD"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 522,
      "preview": "- Phenytoin, phenobarbital"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY",
      "line": 524,
      "preview": "Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 526
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 528,
      "preview": "- Alkalosis"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 529,
      "preview": "- Increased binding of $\\mathrm{Ca}^{2+}$ to albumin"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 530,
      "preview": "- Hypoalbuminemia"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 531,
      "preview": "- Calcium binders"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 532,
      "preview": "- Phosphate replacement products"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 533,
      "preview": "- Citrate (anticoagulant)"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 534,
      "preview": "- Hypomagnesemia"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 535,
      "preview": "- Reduced PTH secretion and activity"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 536,
      "preview": "- Loop diuretics, aminoglycosides, foscarnet, cisplatin, cyclosporine, amphotericin B"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA ETIOLOGY, CONT.",
      "line": 538,
      "preview": "--- page 22 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 540
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 542,
      "preview": "- Acute - hypercalcemia of malignancy"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 543,
      "preview": "- Symptoms"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 544,
      "preview": "- Nausea, vomiting, polyuria, polydipsia, AKI, altered mental status, malignant arrhythmias, coma"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 545,
      "preview": "- Chronic - primary hyperparathyroidism"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 546,
      "preview": "- Symptoms"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 547,
      "preview": "- Renal calcium deposits, metastatic calcifications, CKD"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 548,
      "preview": "- Medication-induced"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 549,
      "preview": "- Vitamin D, calcium supplements, thiazide diuretics"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA (CA > 10.5 MG/DL)",
      "line": 551,
      "preview": "Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum 3rd ed. 2017:113-37."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 553
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 555,
      "preview": "- Correct hypomagnesemia if present"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 556,
      "preview": "- Oral calcium therapy"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 557,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 558,
      "preview": "- Elemental calcium content or oral products varies by salt (9-40\\%)"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 559,
      "preview": "- Adverse effect - constipation"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 560,
      "preview": "- Oral vitamin D therapy"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 561,
      "preview": "- Parenteral calcium therapy"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 562,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "HYPOCALCEMIA MANAGEMENT",
      "line": 564,
      "preview": "--- page 23 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PARENTERAL CALCIUM",
      "line": 566
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 568,
      "preview": "- Empiric calcium dose in PN: 10-15 mEq/day"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 569,
      "preview": "- Always check calcium-phosphate compatibility"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 570,
      "preview": "- Calcium may be removed from PN for short periods in adults"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 571,
      "preview": "- Gluconate salt preferred in PN and peripheral IV"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 572,
      "preview": "- 1 g calcium gluconate $=4.65 \\mathrm{mEq}$ elemental calcium"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 573,
      "preview": "- 1 g calcium chloride $=13.6 \\mathrm{mEq}$ elemental calcium"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 574,
      "preview": "- Bolus dosing versus continuous infusions"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 575,
      "preview": "- Maximum infusion rate: 0.8-1.5 mEq calcium per minute"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 576,
      "preview": "- Adverse effects: infusion-related, hypotension, bradycardia"
    },
    {
      "type": "text",
      "section": "PARENTERAL CALCIUM",
      "line": 578,
      "preview": "Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 580
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 582,
      "preview": "- Identify and treat underlying cause"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 583,
      "preview": "- Hydration $\\pm$ loop diuretics"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 584,
      "preview": "- Calcitonin (rapid onset, tachyphylaxis)"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 585,
      "preview": "- Bisphosphonates (slower onset, longer duration)"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 586,
      "preview": "- Steroids"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 587,
      "preview": "- Surgery (primary hyperparathyroidism)"
    },
    {
      "type": "text",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 589,
      "preview": "--- page 24 ---"
    },
    {
      "type": "image",
      "section": "HYPERCALCEMIA TREATMENT",
      "line": 591,
      "content": "![img-1.jpeg](images/0fc4dfde4f9737bf.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 593
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 595,
      "preview": "A patient presents with serum potassium of $6 \\mathrm{mEq} / \\mathrm{L}$ and peaked T-waves on ECG. "
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 596,
      "preview": "A. Insulin"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 597,
      "preview": "B. Sodium bicarbonate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 598,
      "preview": "C. Calcium gluconate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 599,
      "preview": "D. Sodium polystyrene sulfonate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 601,
      "preview": "--- page 25 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#1",
      "line": 603
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 605,
      "preview": "A patient presents with serum potassium of $6 \\mathrm{mEq} / \\mathrm{L}$ and peaked T-waves on ECG. "
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 606,
      "preview": "A. Insulin"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 607,
      "preview": "B. Sodium bicarbonate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 608,
      "preview": "C. Calcium gluconate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#1",
      "line": 609,
      "preview": "D. Sodium polystyrene sulfonate"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 611
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 613,
      "preview": "Upon morning review of a parenteral nutrition patient, it is noted that the serum magnesium is $1.5 "
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 614,
      "preview": "A. No dose is indicated"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 615,
      "preview": "B. 16 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 616,
      "preview": "C. 32 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 617,
      "preview": "D. 48 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 619,
      "preview": "--- page 26 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#2",
      "line": 621
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 623,
      "preview": "Upon morning review of a parenteral nutrition patient, it is noted that the serum magnesium is $1.5 "
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 624,
      "preview": "A. No dose is indicated"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 625,
      "preview": "B. 16 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 626,
      "preview": "C. 32 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#2",
      "line": 627,
      "preview": "D. 48 mEq magnesium sulfate"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SELF-ASSESSMENT \\#3",
      "line": 629
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 631,
      "preview": "Assuming normal renal function, how much will 30 mmol of potassium phosphate increase the serum pota"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 632,
      "preview": "A. $0.15 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 633,
      "preview": "B. $0.3 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 634,
      "preview": "C. $0.45 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 635,
      "preview": "D. $0.6 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 637,
      "preview": "--- page 27 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SELF-ASSESSMENT \\#3",
      "line": 639
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 641,
      "preview": "Assuming normal renal function, how much will 30 mmol of potassium phosphate increase the serum pota"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 642,
      "preview": "A. $0.15 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 643,
      "preview": "B. $0.3 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 644,
      "preview": "C. $0.45 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "SELF-ASSESSMENT \\#3",
      "line": 645,
      "preview": "D. $0.6 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "CONCLUSIONS",
      "line": 647
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 649,
      "preview": "- A thorough history and physical, including medication review, is important for identification and "
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 650,
      "preview": "- Knowledge of causes of electrolyte disorders will help in determining appropriate prevention and t"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 651,
      "preview": "- Development of a nutrition care plan should be done using a systematic approach including comorbid"
    },
    {
      "type": "text",
      "section": "CONCLUSIONS",
      "line": 653,
      "preview": "--- page 28 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "REFERENCES",
      "line": 655
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 657,
      "preview": "- Canada TW, Lord LM. Chapter 7 Fluid, Electrolytes, and Acid-Base Disorders. In: Mueller CM, ed. Th"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 658,
      "preview": "- Clark CL, Sacks GS, Dickerson RN et al. Treatment of hypophosphatemia in patients receiving specia"
    },
    {
      "type": "text",
      "section": "REFERENCES",
      "line": 659,
      "preview": "- Hammill-Ruth RJ, McGory R. Magnesium repletion and its effect on potassium homeostasis in critical"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "REFERENCES, CONT.",
      "line": 662
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 664,
      "preview": "- Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolytes disorders in adult patients in"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 665,
      "preview": "- Mirtallo J, Canada T, Johnson D et al. Safe practices for parenteral nutrition. JPEN J Parent Ente"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 667,
      "preview": "--- page 29 ---"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 669,
      "preview": "NUTRITION SUPPORT CERTIFICATE"
    },
    {
      "type": "text",
      "section": "REFERENCES, CONT.",
      "line": 671,
      "preview": "--- page 30 ---"
    },
    {
      "type": "image",
      "section": "REFERENCES, CONT.",
      "line": 673,
      "content": "![img-2.jpeg](images/d0651196d10662d6.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Anne M. Tucker, Pharm.D., BCNSP",
      "line": 675
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, Pharm.D., BCNSP",
      "line": 677,
      "preview": "Clinical pharmacy Specialist"
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, Pharm.D., BCNSP",
      "line": 678,
      "preview": "University of Texas MD Anderson Cancer Center Houston, Texas"
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, Pharm.D., BCNSP",
      "line": 680,
      "preview": "Anne M. Tucker is clinical pharmacy specialist at the MD Anderson Cancer Center, Houston, Texas. She"
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, Pharm.D., BCNSP",
      "line": 682,
      "preview": "Dr. Tucker is currently the Chair of the American Society for Parenteral and Enteral Nutrition (ASPE"
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, Pharm.D., BCNSP",
      "line": 684,
      "preview": "--- page 31 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Relevant Financial Relationship Disclosure",
      "line": 686
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 688,
      "preview": "In accordance with our accreditor\u2019s Standards of Integrity and Independence in Accredited Continuing"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 690,
      "preview": "An ineligible company is any entity producing, marketing, re-selling, or distributing health care go"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 692,
      "preview": "The following persons in control of this activity\u2019s content have relevant financial relationships:"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 694,
      "preview": "- Phil Ayers: Fresenius Kabi, consultant and speaker"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 695,
      "preview": "- David Evans: Fresenius Kabi, consultant and speaker; Abbott Laboratories, consultant and speaker; "
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 696,
      "preview": "- Andrew Mays: Fresenius Kabi, speaker"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 697,
      "preview": "- Jay Mirtallo: Fresenius Kabi, consultant"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 698,
      "preview": "- Kris Mogensen: Baxter, speaker; ThriveRx, advisory board; Pfizer, advisory board"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 700,
      "preview": "All other persons in control of content do not have any relevant financial relationships with an ine"
    },
    {
      "type": "text",
      "section": "Relevant Financial Relationship Disclosure",
      "line": 702,
      "preview": "As required by the Standards of Integrity and Independence in Accredited Continuing Education defini"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Methods and CE Requirements",
      "line": 704
    },
    {
      "type": "text",
      "section": "Methods and CE Requirements",
      "line": 706,
      "preview": "This online activity consists of a combined total of 12 learning modules. Pharmacists and physicians"
    },
    {
      "type": "text",
      "section": "Methods and CE Requirements",
      "line": 708,
      "preview": "Participants must participate in the entire activity, complete the evaluation and all required compo"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Important Note \u2013 ACPE 60 Day Deadline:",
      "line": 710
    },
    {
      "type": "text",
      "section": "Important Note \u2013 ACPE 60 Day Deadline:",
      "line": 712,
      "preview": "Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "System Technical Requirements",
      "line": 714
    },
    {
      "type": "text",
      "section": "System Technical Requirements",
      "line": 716,
      "preview": "Courses and learning activities are delivered via your Web browser and Acrobat PDF. Users should hav"
    },
    {
      "type": "text",
      "section": "System Technical Requirements",
      "line": 718,
      "preview": "View Frequently Asked Questions for more information."
    }
  ],
  "images": [
    {
      "sha_name": "dc1fa49c6d641dce.png",
      "original_ref": "img-0.jpeg",
      "page": 1,
      "relative_path": "images/dc1fa49c6d641dce.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/9_ElectrolyteDisorders/images/dc1fa49c6d641dce.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "dc1fa49c6d641dce"
    },
    {
      "sha_name": "0fc4dfde4f9737bf.png",
      "original_ref": "img-1.jpeg",
      "page": 24,
      "relative_path": "images/0fc4dfde4f9737bf.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/9_ElectrolyteDisorders/images/0fc4dfde4f9737bf.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0fc4dfde4f9737bf"
    },
    {
      "sha_name": "d0651196d10662d6.png",
      "original_ref": "img-2.jpeg",
      "page": 30,
      "relative_path": "images/d0651196d10662d6.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/9_ElectrolyteDisorders/images/d0651196d10662d6.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d0651196d10662d6"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754696263",
    "ts": "2025-08-08T23:37:43.345520+00:00"
  }
}